Glenmark completes crofelemer production for Napo

4 December 2006

California, USA-based drugmaker Napo Pharmaceuticals says that India's Glenmark Pharmaceuticals has completed production of the agent crofelemer, for use in a Phase III trial as a treatment for diarrhea in patients with HIV/AIDS.

Glenmark, which carried out production of the active pharmaceutical ingredient at its Food Drug Administration-approved facility in Ankleshwar, India, also licenses the agent for indications which include acute infectious diarrhea, pediatric diarrhea and HIV/AIDS-related diarrhea in 140 countries around the world.

Napo's chief executive, Lisa Conte, said that successful completion of a technology transfer and subsequent production of crofelemer would allow the firm to initiate further trials of the agent to support the HIV/AIDS indication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.